These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
647 related articles for article (PubMed ID: 25462435)
1. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435 [TBL] [Abstract][Full Text] [Related]
2. Reactivation of retinopathy of prematurity after ranibizumab treatment. Wong RK; Hubschman S; Tsui I Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252 [TBL] [Abstract][Full Text] [Related]
3. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis. Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024 [TBL] [Abstract][Full Text] [Related]
4. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192 [TBL] [Abstract][Full Text] [Related]
6. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921 [TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Sankar MJ; Sankar J; Chandra P Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. Gunay M; Sukgen EA; Celik G; Kocluk Y Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302 [TBL] [Abstract][Full Text] [Related]
10. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589 [TBL] [Abstract][Full Text] [Related]
11. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498 [TBL] [Abstract][Full Text] [Related]
12. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children. Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986 [TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity. Cheng HC; Lee SM; Hsieh YT; Lin PK Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity. Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247 [TBL] [Abstract][Full Text] [Related]
20. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results]. Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]